Therapeutic cancer vaccines are a heterogeneous group of complex biologics with distinctly
different clinical characteristics than cytotoxic agents. The current clinical development …

Background—Angiotensin-converting enzyme 2 (ACE2) is a pleiotropic
monocarboxypeptidase capable of metabolizing several peptide substrates. We …

Abstract Background and Objectives Angiotensin-converting enzyme 2 (ACE2) converts
angiotensin II (Ang1-8) to angiotensin 1-7 (Ang1-7), a functional antagonist of Ang1-8, with …

Angiotensin (Ang)-converting enzyme 2 (ACE2) cleaves Ang II to form Ang-(1-7). Here we
examined whether soluble human recombinant ACE2 (rACE2) can efficiently lower Ang II …

OBJECTIVE Diabetic nephropathy is one of the most common causes of end-stage renal
failure. Inhibition of ACE2 function accelerates diabetic kidney injury, whereas renal ACE2 is …

Background Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab,
combined with alternating granulocyte-macrophage colony-stimulating factor and …

Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase capable of
metabolizing angiotensin (Ang) II into Ang 1 to 7. We hypothesized that ACE2 is a negative …

Background Monitoring of circulating tumor cells (CTCs) in blood of carcinoma patients
treated with novel compounds may be a measurement of treatment effectiveness. Before it …

Profilin-1 has recently been linked to vascular hypertrophy and remodeling. Here, we
assessed the hypothesis that angiotensin (Ang) II type I receptor antagonist telmisartan …

Objective: To study angiotensin-converting enzyme 2 in a piglet model with acute respiratory
distress syndrome and to evaluate the therapeutic potential of this substance in a preclinical …